Details for Patent: 5,990,096
✉ Email this page to a colleague
Title: | Formulations containing hyaluronic acid |
Abstract: | The invention relates to a method of controlling the unloading of a drug from the skin or exposed tissue of a human into the lymphatic system comprising transporting an effective dosage amount of the drug into the skin or exposed tissue by an effective non-toxic amount of a form of hyaluronic acid. |
Inventor(s): | Asculai; Samuel Simon (Toronto, CA), Hochman; David (Thornhill, CA), Purschke; Don (Toronto, CA), Harper; David William (Oakville, CA), Klein; Ehud Shmuel (Givat Savyon, IL), Falk; Rudolf Edger (Toronto, CA) |
Assignee: | Hyal Pharmaceutical Corporation (Mississauga, CA) |
Filing Date: | Jun 06, 1995 |
Application Number: | 08/466,713 |
Claims: | 1. A dosage amount of pharmaceutical composition suitable for controlling the unloading of a drug from the skin or exposed tissue of a human into the lymphatic system, the dosage amount comprising pharmaceutical excipients suitable for topical application, an effective non-toxic dosage amount of a drug to treat disease in the lymphatic system in human and an effective non-toxic dosage amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and salts thereof and combination thereof sufficient to control the unloading of the drug into the lymphatic system wherein the effective amount of the form of hyaluronic acid exceeds 5 mg/cm.sup.2 of the skin or exposed tissue and the molecular weight of the form of hyaluronic acid is greater than 150,000 daltons and less than 750,000 daltons and wherein the form of hyaluronic acid present is between 1% to 3% by weight of the dosage amount. 2. A method of controlling the unloading of a drug from the skin or exposed tissue of a human when applied thereto suffering trauma or pathology, into the lymphatic system comprising transporting an amount of a drug into the skin or exposed tissue by an effective non-toxic dosage amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and salts thereof and combination thereof wherein the amount of the form of hyaluronic acid exceeds at least about 5 mg/cm.sup.2 and the molecular weight of the form of hyaluronic acid is greater than 150,000 daltons and less than 750,000 daltons and wherein the form of hyaluronic acid present is between 1% to 3% by weight of the dosage amount. 3. The method of claim 2 wherein the form of hyaluronic acid is sodium hyaluronate being 2.5% by weight of dosage amount and the drug is between 1% to 5% by weight of the dosage amount. 4. The method of claim 3 wherein the drug is a drug which inhibits prostaglandin synthesis. 5. The dosage amount of claim 1 wherein the form of hyaluronic acid is sodium hyaluronate being 2.5% by weight of dosage amount and the drug is between 1% to 5% by weight of the dosage amount and the drug is selected from an NSAID and an anti-cancer drug. 6. The method of claim 4 wherein the drug is selected from an NSAID and an anti-cancer drug. |